Charles River Introduces New Plasmid Manufacturing Program
Platform is expected to streamline batch turnaround times
Charles River Laboratories International, Inc., a contract development and manufacturing organization (CDMO), has launched its branded plasmid platform, XpDNA, which was established from its aforementioned CDMO and biologics testing experience. The company notes that the platform not only reduces plasmid development and production timelines, but simplifies the development process for both cell and gene therapies (CGTs) and vaccine developers.
The program features a plug-n-play screening toolbox for addressing challenging plasmids, phase-appropriate production with fit-for-purpose facilities, on-hand materials, and in-house analytics. The standardized process approach reportedly accelerates batch turnaround times to five weeks for high-quality (HQ) plasmid, and 10 weeks for good manufacturing practice (GMP) plasmid.
“The launch of Charles River’s eXpDNA plasmid manufacturing platform is the latest in a series of portfolio enhancements aimed at supporting vaccine and advanced therapy clients through clinical trials and beyond,” says Kerstin Dolph, Charles River’s corporate SVP of biologic solutions. “By increasing speed and efficiency for plasmid DNA [pDNA] production, eXpDNA will help accomplish our ultimate goal of delivering safe, effective therapies to patients faster.”
Read more about the introduction here.
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
